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The epigenetic regulation of chromatin structure is a major
component of the gene expression regulatory machinery, and this
regulation is accomplished by multiple mechanisms including DNA
methylation and hydroxymethylation, multiple histonemodiﬁcations,
binding molecules, and complex interactions among all these
elements (Jaenisch and Bird, 2003; Mastroeni et al., 2011; Chouliaras
et al., 2013). These complex interactions converge to modulate
chromatin structure, much as multiple inputs converge on the ﬁnal
common path of the anterior horn cells (Sherrington, 1906). By
analogy, we posit chromatin structure as the ﬁnal common path of
multiple epigenetic mechanisms.
Chromatin structure determines whether any selected segment
of DNA is accessible to transcription factors, DNA binding proteins,
or other modiﬁers which govern a gene’s availability for
transcription (Quina et al., 2006). There are multiple classes
of methods for examining chromatin structure. Broadly speaking,
these aremethods that use DNase I digestion, chromatin precipitation,
matrix-assisted reader chromatin capture, and others, which areative Disease Research Center,
University, Tempe, AZ, USA.
n).
Inc. This is an open access article utypically followed by methods to determine location of permissive or
repressive chromatin structure.
In the past, permissive, or open, chromatin has been identiﬁed
by DNase I nuclease sensitivity analysis (Krebs and Peterson, 2000),
and more recently, open chromatin data generated from
DNase-seq have been able to predict cell-type–speciﬁc gene expres-
sion (Natarajan et al., 2012).
An overview of current methods available to ascertain chromatin
structure yields a broad range of approaches, many of which are
variations of chromatin immunoprecipitation (ChIP), an antibody-
based methodology ﬁrst described by Gilmour and Lis (1984, 1985).
Fast carrier ChIP (Fast CChIP) can be used to study transcription factor
binding in small amounts of fresh tissue (Hao et al., 2008). Another
ChIP-based technique uses genomewide chromatin immunoprecipi-
tation in concert with tiling microarrays (ChIP-chip). ChIP-chip, along
with ChIP–quantitative polymerase chain reaction (qPCR), showed
that transcription factor FoxA1 is differentially recruited to cell-type–
speciﬁc enhancers (Lupien et al., 2008). ChIA-PET combines ChIP with
paired-end DNA sequencing to determine global de novo chromatin
interactions (Fullwood et al., 2009). PAT-ChIP, also a ChIP-directed
technique, was used to isolate, extract, and sequence chromatin from
formalin-ﬁxed, parafﬁn-embedded tissue samples (Fanelli et al.,
2010; Fanelli et al., 2011; Amatori et al., 2014). A common method
used to determine chromatin structure is DNase I digestion of DNA
with subsequent sequencing of resulting fragments (DNase-seq).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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suggesting areas of the chromatin accessible to DNase digestion to be
“open” and poised for transcription. A recent international epigenetic
collaborative study, Encyclopedia of DNA Elements (ENCODE),
created a genomewide map of DHSs in 125 human cell lines and
tissue types and correlated those sites with ChIP-seq data (Thurman
et al., 2012). In addition to genomewide mapping of DHS, DNase I
sensitivity and sequencing can be used to analyze receptor binding
inﬂuences on chromatin structure at speciﬁc gene loci in vitro
(Tewari, et al., 2012). More recently, a modiﬁcation to ChIP-Seq,
called Bar-ChIP, allowed multiple DNA-protein interactions to be
simultaneously proﬁled by attaching molecular barcodes to chromatin
fragments from Saccharomyces cerevisiae (Chabbert et al., 2015).
Chromosome conformation capture (3C) technologies have been
used formore than a decade. First described in Dekker et al. (2002), 3C
delivers 3-dimensional chromatin structure information based on
interaction frequencies between genomic loci. Some 3C technologies,
such as e4C, use ChIP within the protocol (Sexton et al., 2012).
Capture-C, the most recent derivative of the 3C technique,
modiﬁes the 3C method into a multiplexed, high-throughput
approach to analyzing cis-acting elements that control gene expression
(Hughes et al., 2014).
A ChIP-less technique to examine the epigenome, called MARCC
(matrix-assisted reader chromatin capture), is a platform that probes
combinatorial histone modiﬁcation patterns to determine functional
chromatin conformation (Su et al., 2014). Finally, direct chromatin
PCR is a method for gene-speciﬁc chromatin analysis performed on
cultured cells using properties of standard PCR buffers and thermal
cycling temperatures to amplify open regions of chromatin (Vatolin,
et al., 2012).
Although ChIP and non–ChIP-based techniques have been broadly
used in elucidating chromatin structure and its impact on gene
regulation, caveats to their use exist. The ChIP-based techniques rely
on antibodies, which involve problems with antibody speciﬁcity and
optimization (Orlando, 2000). Moreover, most ChIP and non–ChIP-
based methods need large amounts of cultured cells or fresh tissue to
start with. In addition, these complicated protocols take several days to
complete and can be expensive with labor, reagents, equipment, and
per-sample core costs (Shefﬁeld and Furey, 2012).
A major limitation of DNase I–based methods is the susceptibility of
DNase I to inhibition by actin, a component of many cells and tissues.
Recently, a protocol was developed for determining chromatin
accessibility in frozen tissue homogenates using Benzonase, a robust
nuclease whose efﬁcacy is not affected by the presence of actin
(Grøntved et al., 2012). Herewe describe a protocol to assess chromatin
structure at speciﬁc loci using Benzonase digestion and qPCR of DNA
extracted from frozen tissue homogenates and laser capture dissected
deﬁned cells. This protocol is relatively quick, inexpensive, and
achievable in any research laboratory outﬁtted with standard real-time
PCR equipment. This novel method will allow a more focused
examination of chromatin structure, its inﬂuence on gene expression,
and the impact it may have on gene expression in normal and diseased
brain as well as other tissues.Table 1
Primer sequences used for qPCR to determine chromatin accessibility
Gene Forward Reverse
KAT6B CCCCAATGGGCTGCAGAGTGGTTAG CGCTGCCGCTGCCTGAGAAACT
APP CTCCCACTGTTCACGAAGCCCAGGT CTACCGCTGCCGAGGAAACTGACG
ARC1 GGGCCTCGCTGGCTGCATAAAGAG GTCCGGTGGTCCAGCTCCATCTGT
ARC2 ACTCGCAGCGCTGGAAGAAGTCCAT GCGTAGGGGCTGACGGTGTAGTCGT
ARC3 TGGTCCTTCACTGCCCACTCTCCTG CTAAGCTGGGGCTCCTGCCCTCTG
ARC4 ATGAGCTCCTCCCCAGACCCCAGAC GCAGTGAAGGACCACGCAGGACAGT
RPS28 AGAGCGAAGGGTCCCGGCTTAGGAG AGAGGAGTCACGTGCTTCGGGGAGA
GAPDH AAAAGCGGGGAGAAAGTAGG AGAGGAGTCACGTGCTTCGGGGAGA
CTCF4 CCCCAGAGAGTAGGGAACAG GGCACGCAAAGACATACTGA
CTCF10 AGAGCACCCCCTACTGGCTAA TAAGAAGCTGTGCGCGATGAC2. Materials and methods
2.1. Tissue (samples)
All frozen brain tissue samples and frozen brain sections were
obtained from the Brain Bank at Banner Sun Health Research Institute.
Average postmortem delay at this Brain Bank is 2.6 hours. Homogenate
studies used approximately 1 g of middle temporal gyrus (MTG) and
cerebellum (CBL) from each of 3 nondemented controls (NDs) and 3
Alzheimer's disease (AD) cases. Laser capture microdissection (LCM)
studies used 10-μmserial sections ofMTG (area 22) from1NDand 1 ADcase and 10-μm serial sections of hippocampus from 5 ND and
5 AD cases.
2.2. Primers
2.2.1. Primer design for chromatin accessibility analysis
Primers for KAT6B, APP, and RSP28 were designed to cover the
area 300 base pairs (bp) upstream of the transcription start site and
100 bp downstream of the transcription start site. The primer
sequences for GAPDH, CTCF4, and CTCF10 were taken from He et al.
(2014) and chosen to represent areas of the genome known to be
constitutively open (GAPDH) and/or uniform in openness across
sample types (CTCF4, CTCF10) (Li et al., 2013). All primers were
checked for speciﬁcity via the National Center for Biotechnology
Information's BLAST search.
To examine chromatin structure in multiple regions of 1 gene,
primers for ARC were designed based on ENCODE data (Thurman
et al., 2012). ARC1 was located in the promoter region, an area
identiﬁed with high signiﬁcance as open chromatin and validated by
DNase I hypersensitivity and formaldehyde-assisted isolation of
regulatory elements (FAIRE) assays. This area contained DNase I
hypersensitivity in 113 of 125 cell lines/types. Transcription factor
ChIP-seq data show it to be densely populated with DNA binding
proteins (transcription factors, transcription machinery components,
chromatin factors) with varying degrees of occupancy. ARC2 was
located adjacent to ARC1, breaching the start of the coding sequence.
This area was validated by both DNase I hypersensitivity and FAIRE
assays with DNase I hypersensitivity in 16 of 125 cell lines/types.
ChIP-seq data identiﬁed several DNA binding proteins with varying
degrees of occupancy. ARC3 was located near the end of the gene in
the third exon. This area contained DNase I hypersensitivity in 10 of
125 cell lines/types. This region was considered high signiﬁcance as
open chromatin but not validated by both DNase I and FAIRE assays.
Transcription factor CTCF occupancy is shown to be weak. ARC4 was
designed in an area that could be considered a “control,” an intronic
region between exons 2 and 3.
To determine the optimal annealing/extension temperatures for
all primer sets designed, a gradient PCR with melting curve was run.
Based on the results of the gradient, a standard curve PCR was
performed to test the PCR efﬁciency. Efﬁciency greater than 90% was
acceptable. After optimizing PCR protocols, the samples were run
within those parameters. Primer sequences are found in Table 1.
2.3. Brain homogenates
2.3.1. Benzonase digestion (adapted from Grøntved et al., 2012)
Approximately 600 mg of frozen brain tissue was pulverized with
a mortar and pestle that had been prechilled on dry ice. The
pulverized tissue was transferred to a prechilled 15-mL tube and
then suspended in 4 mL of lysis buffer (30 mmol/L Tris-HCL [pH 8.0],
2 mmol/L EDTA, 2 mmol/L EGTA, 20 mmol/L sodium butyrate,
2 mmol/L sodium orthovanadate, 4 mmol/L sodium ﬂuoride, protease
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needle. Volume was brought up to 6 mL with lysis buffer. Using a
23-gauge needle, the suspension was mixed and distributed in 500-μL
equal-volume aliquots into 2-mL microfuge tubes and incubated on
ice for 5 minutes. Aliquots not needed were frozen at 20°C for later
use. To the aliquots being used, 500 μL of nuclease digestion buffer
(30 mmol/L Tris-HCL [pH 8.0], 14 mmol/L MgCl2, 0.5% NP-40, 0.2%
fatty acid–free bovine serum albumin, 0.25 U/μL Benzonase [EMD
Millipore]) was added. A no-nuclease control sample was also prepared.
The tubes were gently inverted to mix and incubated at 37°C for
3 minutes. Immediately after the incubation, EDTA (at 50-mmol/L ﬁnal
concentration) and sodium dodecyl sulfate (SDS) (at 0.1% ﬁnal
concentration) were added to stop the digestion reaction. Fifty
microliters of RNaseA/RNaseT1 (Ambion/Life Technologies) was added
and incubated overnight at 45°C. After incubation, SDSwas added toﬁnal
concentration of 0.75% and placed at 45°C for 2 hours. Proteinase K
(Sigma) was then added to ﬁnal concentration of 0.8 μg/mL and
incubated overnight at 45°C. Digested and undigested DNA reactions
were puriﬁed by gel extraction (Wizard SV Gel and PCR Clean Up,
Promega) or phenol chloroformextraction and ethanol precipitation and
then quantiﬁed with Quant-iT PicoGreen Assay (Life Technologies).
2.3.2. Chromatin accessibility analysis by qPCR
(adapted from Rao et al., 2001)
Five nanograms of digested and undigested DNA from each sample
was ampliﬁed in triplicate for 50 cycles on an iCycler iQ (Bio-Rad)
using EpiQ SYBR Green Supermix (Bio-Rad) (This supermix was
discontinued in early stages of protocol design. iTaq Universal SYBR
Green Supermix [Bio-Rad] was used for remaining experiments.) and
2-μmol/L primers under the optimized parameters for each primer
set. In the resulting PCR analyses, higher CT values indicate more
“open” chromatin accessible to regulatory elements.
2.4. Laser capture microdissected derived cells
2.4.1. Benzonase digestion of many cells
Ten-micrometer frozen sections of hippocampus from (5) AD and
(5) ND cases were mounted on PEN slides (Leica) and kept under
desiccant at−80°C until use. After a brief thaw, sections were placed
in 100% EtOH then 95% EtOH and a ﬁnal 70% ethanol for 5 seconds
each then rinsed with molecular grade water. Neutral red stain (1%)
was applied for 30 seconds and then rinsed twice with molecular
gradewater and dehydrated for 5 seconds in 70% EtOH then 95% EtOH
and for 1 minute in 100% ethanol. Laser capture microdissection of
dentate gyrus granule cells was performed on an LMD 6500 (Leica).
Brieﬂy, 40 μL of lysis buffer (20 mmol/L Tris-HCL [pH 7.5], 2 mmol/L
EDTA, 1 mmol/L EGTA, 0.5% glycerol, 20 mmol/L sodium butyrate,
2 mmol/L sodium orthovanadate, 4 mmol/L sodium ﬂuoride, protease
inhibitor cocktail [Pierce]) was added to the cap of the tube where the
sample was captured. After a 1-minute spin, another 40 μL of lysis
buffer was added to the cap. The tube was set upside down on a bench
for 20 minutes, spun down in a bench top centrifuge for 1 minute, and
then split equally (40 μL) into 2 tubes for no-enzyme control and
enzyme digestion. For enzyme digestion, 40-μL nuclease digestion
buffer (40 mmol/L Tris-HCL [pH 8.0], 6 mmol/L MgCl2, 0.3% NP-40, 1%
glycerol, 0.25 U/μL Benzonase [EMD Millipore]) was added. The
no-nuclease control tube received 40 μL of nuclease digestion buffer
minus the Benzonase. Both tubes were placed at 37°C for 2.5 minutes.
To stop the reaction, EDTA (10 mmol/L ﬁnal) and SDS (0.75% ﬁnal)
were added to each tube. Then, 4 μL RNaseA/RNase T1 was added, and
the tubes were placed at 45°C overnight. The next day, SDS at 0.75%
ﬁnal concentration was added and incubated for 2 hours at 45°C.
Next, Proteinase K (0.5 μg/mL ﬁnal) was added and incubated
overnight at 45°C. The digested and undigested DNA reactions were
puriﬁed by phenol chloroform extraction and ethanol precipitation.2.4.2. Chromatin accessibility analysis by qPCR of many cells
(dentate gyrus granule cells)
Digested and undigested DNA from each sample was ampliﬁed in
duplicate for 50 cycles on an iCycler iQ (Bio-Rad) using iTaq Universal
SYBR Green Supermix (Bio-Rad) and 2-μmol/L primers under the
optimized parameters for each primer set.
2.4.3. Benzonase digestion of few cells
Ten-micrometer frozen serial sections of MTG from (1) AD and (1)
ND caseweremounted on PEN slides (Leica) and kept under desiccant
at −80°C until use. After brief thaw, sections were stained with 1%
neutral red to identify pyramidal neurons. Neuroﬁbrillary tangle-
bearing neurons were identiﬁed by staining an adjacent section with
0.1% Thioﬂavin S for 15 seconds. Non–tangle-bearing pyramidal
neurons were chosen after comparing the adjacent sections and
excluding tangle-bearing cells. Laser capture microdissection of
nontangle neurons was performed on a PALM MicroBeam (Zeiss)
where approximately 50 cells were captured into AdhesiveCap tubes
(Zeiss). Twenty microliters of lysis buffer (20 mmol/L Tris-HCL
[pH 7.5], 2 mmol/L EDTA, 1 mmol/L EGTA, 0.5% glycerol, 20 mmol/L
sodium butyrate, 2 mmol/L sodium orthovanadate, 4 mmol/L sodium
ﬂuoride, HALT protease inhibitor cocktail [Pierce]) was added to the
cap of the tube. The tube was set upside down on a bench for
20 minutes and then spun down in a bench top centrifuge for
1 minute. An additional 10 μL of lysis buffer was added to the tube
and then split equally (~15 μL) into 2 tubes for no-enzyme control and
enzyme digestion. For enzyme digestion, 15-μL nuclease digestion
buffer (40 mmol/L Tris-HCL [pH 8.0], 6 mmol/L MgCl2, 0.3% NP-40, 1%
glycerol, 0.25 U/μL Benzonase [EMD Millipore]) was added. The
no-nuclease control tube received 15 μL of nuclease digestion buffer
minus the Benzonase. Both tubes were placed at 37°C for 2.5 minutes.
To stop the reaction, EDTA (10 mmol/L ﬁnal) and SDS (0.75% ﬁnal)
were added to each tube. Then, 1.5 μL RNaseA/RNase T1 was added,
and the tubes were placed at 45°C overnight. The next day, SDS at
0.75% ﬁnal concentration was added and incubated for 2 hours at
45°C. Next, Proteinase K (0.5 μg/mL ﬁnal) was added and incubated
overnight at 45°C. The digested and undigested DNA reactions were
puriﬁed by phenol chloroform extraction and ethanol precipitation.
2.4.4. Chromatin accessibility analysis by qPCR of few cells
(non–tangle-bearing neurons)
Approximate equivalents of 5 cells underwent qPCR on an iCycler
iQ (Bio-Rad) with the same APP primers and conditions as with frozen
homogenates protocol except that the cycle number was extended to
80 cycles because of the minute amount of starting material. A 1.5%
agarose gel was run to verify ampliﬁcation of 260-bp amplicon (data
not shown).
2.5. Validation in vitro by treatment of cells with a reagent known
to lead to open, permissive chromatin
2.5.1. Valproic acid treatment to decondense chromatin in SH-SY5Y cells
SH-SY5Y neuroblastoma cells (ATCC) were cultured and main-
tained in a humidiﬁed 37°C incubator with 5% CO2 in complete
Dulbecco modiﬁed Eagle medium (DMEM) (DMEMwith high glucose
[Life Technologies], 10% fetal bovine serum [Gemini Bio-Products], 2%
HEPES [Irvine Scientiﬁc], 1% sodium pyruvate [Thermo Scientiﬁc], 1%
penicillin/streptomycin [Life Technologies], and 0.1% gentamycin [Life
Technologies]). After 4 days in culture, cells were seeded at a density
of 2.6 × 105 cells/mL in 6-well plates. Two days later, they were fed
with complete DMEM, and half the wells were treated with 1 mmol/L
valproic acid (VPA) (Sigma), an HDAC inhibitor known to decondense
chromatin (Felisbino et al., 2011; Felisbino et al., 2014), and half were
left untreated. After incubating for 24 hours at 37°C and 5% CO2, they
were washed twice in 1× phosphate-buffered saline, collected by
centrifugation, washed twice in ice-cold wash buffer (20 mmol/L
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sodium butyrate, 10 mmol/L sodium orthovanadate, 2 mmol/L sodium
ﬂuoride, 1×HALTprotease inhibitor cocktail [Pierce]), and resuspended
in 1-mL lysis buffer (20 mmol/L Tris-HCl [pH 7.5], 2 mmol/L EDTA,
1 mmol/L EGTA, 20 mmol/L sodium butyrate, 2 mmol/L sodium
orthovanadate, 4 mmol/L sodium ﬂuoride, 0.5% glycerol, and 1× HALT
protease inhibitor cocktail [Pierce]) and aliquot 500 μL to 2 tubes, one
for enzyme digestion and one no-enzyme control. Next, Five hundred
microliters of nuclease digestion buffer (40 mmol/L Tris-HCl [pH 8.0],
6 mmol/L MgCl2, 0.3% NP-40, and 1% glycerol) was added to each tube.
Benzonase was added to appropriate tubes for a ﬁnal concentration of
0.5 U/mL. Tubes were incubated at 37°C for 3 minutes. To stop the
reaction, EDTA (10 mmol/L ﬁnal) and SDS (0.75% ﬁnal) were added to
each tube.Next, ProteinaseK (0.5 μg/mLﬁnal)wasaddedand incubated
overnight at 45°C. The digested and undigested DNA reactions were
puriﬁed by phenol chloroform extraction and ethanol precipitation and
quantiﬁed by Quant-iT PicoGreen Assay (Life Technologies). Digested
and undigested DNA (5 ng) from each sample was ampliﬁed in
duplicate on an iCycler iQ (Bio-Rad) using iTaq Universal SYBR Green
Supermix (Bio-Rad) and 2-μmol/L primers as per the optimized
parameters determined by gradient and melting curve PCR.
2.6. Validation in vitro by comparison of Benzonase with DNase I
digestion in SH-SY5Y cells
SH-SY5Y cells were cultured and maintained as described above.
Four concentrations of Benzonase (none, 0.33 U, 1 U, 3 U) were used
to digest 3.4 × 106 cells as detailed above. The DNase I digestion
protocol was based on Song and Crawford (2010). For DNase I
digestion, 3.7 × 107 cells were pelleted in a 15-mL tube and then
resuspended by gentle ﬂicking in 1 mL ice-cold resuspension buffer
(RSB) (10 mmol/L Tris-HCl [pH 7.4], 10 mmol/L NaCl, 3 mmol/L
MgCl2). Lysis buffer (RSB + 0.1% IGEPAL CA-630 [Sigma]) was poured
slowly into the tube and then centrifuged (500g) at 4°C for
10 minutes. Supernatant was completely removed, and nuclei were
resuspended in 600 μL of cold RSB by gentle ﬂicking. The nuclei were
aliquoted equally into 5 microfuge tubes containing different
concentrations of DNase I (Sigma) (none, 0.12 U, 0.4 U, 1.2 U, 4 U).
Tubes were incubated at 37°C for 11 minutes. To stop the reaction,
160 μL of 50 mmol/L EDTA was added, and tubes were inverted 5
times to mix. The digested and undigested DNA reactions were
puriﬁed by phenol chloroform extraction and ethanol precipitation
and quantiﬁed by Quant-iT PicoGreen Assay (Life Technologies).
Digested and undigested DNA (5 ng) from each sample was ampliﬁed
in duplicate on an iCycler iQ (Bio-Rad) using iTaq Universal SYBR
Green Supermix (Bio-Rad) and 2-μmol/L primers as per the optimized
parameters determined by gradient and melting curve PCR.
3. Results
3.1. Homogenate samples
3.1.1. 1 case of AD, promoter region of 2 genes in 2
different brain regions
For proof of concept, brain homogenates from MTG and CBL of 1
AD case were digested with Benzonase. The ampliﬁcation curves of
the digested and undigested samples for genes KAT6B and APP
demonstrate that undigested DNA has the lowest CT values for both
genes and brain regions, and the promoter regions of KAT6B and APP
are more open in MTG than CBL (Fig. 1). APP plays a prominent role in
Alzheimer's pathology, and increased expression of KAT6B, a lysine
acetyltransferase, has been associated with decreased expression of
synaptophysin, a presynaptic molecule. Because the MTG is more
affected in AD than is the CBL, it can be expected that the promoter
regions of these genes would be more permissive in the MTG,consistent with literature showing CBL to be less affected thanMTG in
Alzheimer's disease.
3.1.2. More cases and 2 brain regions with comparison of Alzheimer's
and control samples
Subsequently, the number of cases was increased to MTG and CBL
of 3 ND and 3 AD cases. InMTG, KAT6B and APPweremore open in AD
than ND (Fig. 2A). The results also showed that in CBL, KAT6B and APP
were more open in AD as compared with ND (Fig. 2B), suggesting
some effect of AD in CBL, although less than in MTG, replicating the
conclusion from Fig. 1 that MTG is more affected than CBL (compare
relative heights of bars in Fig. 2A, temporal gyrus, and 2B, CBL). CT
values indicate that both genes aremore open inMTG (Fig. 2A) than in
CBL (Fig. 2B).
3.1.3. More regions within 1 gene—homogenates of MTG
Up to this point, chromatin accessibility analysis was limited to the
promoter region of genes. To demonstrate ability to examine multiple
regions within 1 gene, primers were designed for 4 regions of the Arc
gene. Arc was selected for study because of its role as an immediate
early gene important for memory (Guzowski et al., 2000). Four
regions within the Arc sequence were chosen based on DNase I
sensitive sites and H3K4Me3 ChIP analysis from the ENCODE project
(Thurman et al., 2012). In this brain region, analysis of variance
(ANOVA) shows differential relative openness among the 4 arc
regions examined (P = 0.01). The promoter region of Arc (ARC1) is
signiﬁcantly less open in AD than in ND (t test P b .05) (Fig. 3),
consistent with the deﬁcient memory function characteristic of
Alzheimer's disease.
3.2. Laser capture samples
3.2.1. Many dentate gyrus granule cells
To test compatibility of our protocol with LCM, we used a Leica
LMD 6500 to dissect a portion of the dentate gyrus granule cell layer
followed by Benzonase digestion and qPCR for 4 regions of the ARC
gene. Fig. 4 shows representative qPCR traces of the promoter region
of ARC from 1 ND and 1 AD case (Fig. 4A) and of an intronic region of
ARC in 1 ND and 1 AD case (Fig. 4B). The CT values of all undigested
samples are comparable and lower than digested samples, as
expected. ANOVA analysis of the CT values showed no signiﬁcant
difference between primer groups and no signiﬁcant difference in
openness betweenNDand AD in any of the gene regions (t test) (Fig. 5).
For example, in support of this analysis seen in Fig. 4B, the qPCR traces of
ARC4 in digestedNDandAD samples showthat chromatin appears to be
equally accessible. This result differs from the result shown for
homogenate data in Fig. 3. We emphasize that this is a different brain
region inwhichneurons donot typically show the neuroﬁbrillary tangle
pathology of Alzheimer's disease and granule cells of the dentate gyrus
are not lost in AD (West et al., 1994).
3.2.2. Few MTG pyramidal neurons
To test the lower limit of the protocol, layer 3 pyramidal neurons
from 1 ND and 1 AD case with no tangle pathology were selected in
MTG and captured via LCM. Samples equaling 5 cell equivalents were
subjected to Benzonase digestion and chromatin accessibility for APP
determined by PCR. The data indicate that the promoter region of the
APP gene is less open in AD than in NDs (Fig. 6). A 1% agarose gel
indicated PCR products at the appropriate size (data not shown).
These data indicate that this protocol can be used on as few as 5 laser
captured cells but appear contradictory to the homogenate data. We
can theorize as to why the difference in results, from the heteroge-
neity of cells in homogenates masking the data (Wills et al., 2013) to
the minute starting material from single cells confounding the data.
Nevertheless, we assert that without additional samples and
Fig. 1.MTG and CBL homogenates of frozen tissue from 1 AD case underwent Benzonase digestion then qPCR to determine relative openness of chromatin in the promoter region of
APP and KAT6B. qPCR traces show that the promoter regions of KAT6B and APP appear to be more accessible in MTG than in CBL. The lower CT values of the uncut samples are
consistent with intact/undigested DNA.
Fig. 2.MTG and CBL homogenates of frozen tissue from 3 ND and 3 AD cases underwen
Benzonase digestion then qPCR to determine relative openness of chromatin in the
promoter region of APP and KAT6B. (A) In MTG, promoter regions of KAT6B and APP
appear to be more open in AD than ND. *Student t test P b .05. (B) In CBL, promoter
regions of KAT6B and APP appear to be more open in AD than ND. *Student t tes
P b .05. Abbreviations: D, Benzonase digested; U, undigested. Error bars signify SEM.
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of APP in ND or AD in non–tangle-bearing neurons of the MTG.
3.3. Validation
3.3.1. By treatment known to open chromatin
We treated SH-SY5Y cells with VPA, an HDAC inhibitor known to
decondense chromatin (Marchion et al., 2005). The prediction was
that VPA-treated cells would show more open chromatin than cells
not treated with VPA. Fig. 7 shows this to be true for the promoter
region of KAT6B and APP genes, with equivocal results in the
promoter region of Arc (ARC1) (Fig. 7). The lack of effect that VPA
had on Arc could be inherent to SH-SY5Y cells. Past studies found that
Arc expression in these cells is a ﬁne-tuned balancing act between
translation-dependent mRNA decay and proteasomal degradation,
and without speciﬁc stimulation, Arc expression is negligible (Soulé
et al., 2012). This leads us to consider that regulation of Arcmay not be
so dependent on histone acetylation; thus, VPA may not act on the
chromatin in the promoter region of Arc the same way as with KAT6B
and APP.
The results of the chromatin accessibility analysis showed no
difference in relative openness in the no-Benzonase digestion in
VPA-treated and untreated cells but large increases in openness in
VPA-treated cells digested with Benzonase, as expected (Fig. 7).
In addition, it appeared that the VPA relaxed the chromatin in
the primer-speciﬁc areas of KAT6B and APP, with a signiﬁcant
difference in relative openness between VPA treated without
Benzonase digestion and VPA treated plus Benzonase digestion with
Student t test of P b .05 (Fig. 7).
3.3.2. By comparison with DNase I
To further validate our Benzonase protocol, we compared it with
conventional DNase I digestion, the standard method for determining
active, or “open,” areas of chromatin (Krebs and Peterson, 2000).t
t
Fig. 3. MTG homogenates from 3 ND and 3 AD cases underwent Benzonase digestion
and qPCR. Four regions of the ARC gene were examined for chromatin accessibility.
ANOVA between primer groups was P = 0.01. *Student t test (P b .05) showed that AD
is signiﬁcantly less open than ND in the promoter region of the gene (ARC1).
Abbreviations: ND (−), nondemented control undigested; AD (−), Alzheimer's disease
undigested; ND (+), nondemented control Benzonase digested; AD (+), Alzheimer's
disease Benzonase digested. Error bars signify SEM.
Fig. 4. Dentate gyrus granule cells from 5 ND and 5 AD cases were obtained via LCM and und
regions of the ARC gene. (A) Graph is representative of qPCR traces in the promoter region o
intronic region of Arc (ARC4) from 1 ND and 1 AD case. As predicted and seen in bo
Benzonase-digested samples.
6 E. Delvaux et al. / Neuroepigenetics 6 (2016) 1–9To compare Benzonase digestion to DNase I digestion, we analyzed
chromatin accessibility in 7 distinct regions of the genome after
digesting SH-SY5Y cells with selected concentrations of each enzyme.
Comparison of the peaks in the Benzonase-digested cells (Fig. 8A) to
those in the DNase I–digested cells (Fig. 8B) showed similar patterns
of relative openness, substantiating that the 2 enzymes function
comparably. To determine the effect of concentration of DNase I and
Benzonase on our data, we converted the data to standard scores. The
resulting standard scores are presented in Fig. 8C, which indicates that
under the conditions examined and over the concentration ranges
used, Benzonase and DNase I act very similarly.
4. Discussion
We have described a new method for examining chromatin
structure that digests DNA with Benzonase to avoid the problems
posed by actin when using DNase I. We have demonstrated the
application of this method to homogenates of brain tissue, to laser
microdissected brain tissue, to small numbers of neurons obtained by
LCM, and to in vitro cell preparations. We have demonstrated theerwent Benzonase digestion and qPCR to determine relative openness of chromatin in 4
f Arc (ARC1) from 1 ND and 1 AD case. (B) Graph is representative of qPCR traces in an
th A and B, undigested samples should have equivalent and lower CT values than
Fig. 5.Dentate gyrus granule cells from 5 ND and 5 AD cases were obtained via LCM and
then underwent Benzonase digestion and qPCR. Four regions of the ARC gene were
examined for chromatin accessibility. No signiﬁcant difference was found between
primer groups or in accessibility between ND and AD in any of the gene regions. Error
bars signify SEM.
Fig. 7. To validate Benzonase efﬁcacy, SH-SY5Y cells were treated with VPA, an agen
known to relax chromatin, and then digested with Benzonase. qPCR results indicate
that VPA relaxed the chromatin in the primer-speciﬁc areas of KAT6B and APP with
signiﬁcant difference in relative openness between VPA-treated cells with and withou
Benzonase digestion with Student t test of P b .05*. Abbreviations: U-B, untreated and
no Benzonase digestion; VPA-B, VPA treated and no Benzonase digestion; VPA + B
VPA treated and Benzonase digested. Error bars signify SEM.
7E. Delvaux et al. / Neuroepigenetics 6 (2016) 1–9applicability of this method to examination of multiple genes as well
as multiple sites within 1 gene. We have experimentally demonstrated
the validity of our method by treating cells with valproate, a reagent
known to render chromatin more permissive, and by comparison with
DNase I digestion.
The premise behind our chromatin accessibility analysis using a
nuclease and qPCR is that “open” chromatin will be subject to enzyme
cleavage; therefore, less available to amplify in qPCR; leading to
higher CT values. Meaning, the higher the CT value is, the more
accessible the chromatin is for initiation of transcription. Our novel
protocol uses Benzonase, a nuclease that can successfully digest
chromatin and whose efﬁcacy is not inhibited by actin, as is the case
with DNase I (Lazarides and Lindberg, 1974).
Initial experiments in frozen brain homogenates from 1 AD case
demonstrated differential chromatin “openness” between 2 brain
regions, as well as between 2 genes of interest. In this case, the
promoter region of KAT6B and APP appeared more open in MTG than
in CBL. When the number of cases was increased to compare
chromatin accessibility between brain regions and disease states,Fig. 6. Five cell equivalents of MTG layer 3 pyramidal neurons with no tangle pathology from 1 ND and 1 AD case were acquired via LCM and then underwent Benzonase digestion
and qPCR to determine relative openness of chromatin in the promoter region of APP. qPCR traces show that the promoter region of APP appears to be more accessible in ND than
in AD.t
t
,the results showed that deﬁned regions of both genesweremore open
in AD than ND in both brain regions and that both genes are more
open in MTG than CBL, conﬁrming the previous study.
When we tested the lower limits of our protocol on 5 neurons
obtained by LCM, we yielded seemingly different results than shown
in the homogenates. We can speculate that cell heterogeneity in
homogenates can mask the results that we may observe down
to single-cell to few-cells level (Wills et al., 2013). Nevertheless,
we emphasize that, without additional samples and replicates, we
cannot draw a valid conclusion on chromatin accessibility from our 5
cell data.
We also used our method to examine chromatin structure at
multiple sites within 1 gene. ARC was interrogated at 4 sites in MTG
homogenate samples. Results showed that the promoter region of the
ARC gene was signiﬁcantly less open in AD than ND. When done on
the dentate gyrus of LCM samples, there was no signiﬁcant difference
found in any of the 4 regions of the gene. We stress that this is a
Fig. 8. To compare Benzonase to DNase I, SH-SY5Y cells were digested with various
concentrations of Benzonase (A) or DNase I (B). qPCR indicated that Benzonase
digestion exhibited similar patterns of relative openness to DNase I digestion in 7
distinct regions of the genome. (C) Standard scores (x-m/sd) of CT data validate that
DNase I and Benzonase are comparable under the conditions examined. Error bars
signify SEM.
8 E. Delvaux et al. / Neuroepigenetics 6 (2016) 1–9different brain region in which neurons do not typically show the
neuron loss (West et al., 1994) or neuroﬁbrillary tangle pathology of
Alzheimer's disease. Therefore, the ﬁnding of no difference between
AD and ND in this region is to be expected.
Validation experiments began with treating SH-SY5Y cell with
VPA, an agent known to decondense chromatin (Marchion et al.,
2005). The treatment relaxed the chromatin as expected, validated by
showing that the chromatin in VPA-treated cells digested with
Benzonase was more open than that in cells not digested. Finally,
when comparing chromatin structure (accessibility) in SH-SY5Y cells
that had been digested with Benzonase to those digested with DNase I,
the criterion standard used for chromatin studies in cultured cells,
similar patterns emerged. This concluding validation step demonstrates
the efﬁcacy and usefulness of Benzonase for chromatin structure
analysis studies.
New methods to determine chromatin accessibility seem to arise
at a consistent pace. One of the most recent examines chromatin
structure at the single-cell level, however, only in cultured cells(Buenrostro et al., 2015). Up until now, no method existed to
determine chromatin structure in frozen tissue samples at the level of
deﬁned cells. The protocol detailed here bridges that gap. This
proposed novel method for frozen tissue demonstrates the capability
to choose speciﬁc cell types to interrogate based on disease versus
nondisease, or cells that express a particular protein, cells of a certain
morphology, or cells in particular regions of tissue. This potential
could translate into the ability to identify speciﬁc regulatory mechanisms
implicated in disease or normal cellular processes.
Numerous epigenetic mechanisms converge to modulate
chromatin structure, and many methods exist to delineate this
structure. Most of these methods require considerable amounts of
starting material, personnel time, reagent costs, and expensive
equipment. The protocol we describe investigates chromatin structure
at distinct genomic loci from frozen tissue and deﬁned cells obtained by
LCM. In addition, the protocol is rapid, inexpensive, and easily executed
in a typical research laboratory setting.Disclosure statement
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